Skip to content
2000
Volume 8, Issue 4
  • ISSN: 1871-5222
  • E-ISSN: 1875-6115

Abstract

We briefly summarize evidence from non-clinical and clinical studies that amylin agonism has a physiological role in glucose and body weight regulation. Next, the amylin analog pramlintide is highlighted as part of an integrated neurohormonal therapeutic approach in both diabetes and weight management. Finally, attributes of, and analoging strategies to, the amylin molecule are discussed with the goal of improving targeted properties leading to the development of an optimized therapeutic candidate.

Loading

Article metrics loading...

/content/journals/iemamc/10.2174/187152208787169189
2008-12-01
2025-09-11
Loading full text...

Full text loading...

/content/journals/iemamc/10.2174/187152208787169189
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test